SightfileU.S. market data from official filings

Aytu BioPharma Inc (AYTU)

Name: Aytu BioPharma Inc (AYTU) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001385818 · EDGAR filings · Updated 2026-06-25

Aytu BioPharma Inc (AYTU) has reported institutional ownership of 36.4%, with 36 institutional managers holding positions valued at $10.7M per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Institutional ownership

36.4%

Institutional managers

Reported 13F value

$10.7M

Insider activity

15 trans.

$132.9K net buying

Data flags

3 active

from SEC filings

Latest updates

2026-06-25 — Current report (8-K) filed
2026-05-13 — Quarterly report (10-Q) filed
2026-05-13 — Current report (8-K) filed
2026-04-02 — Current report (8-K) filed
2026-02-17 — SCHEDULE 13G/A filed
2026-02-13 — SCHEDULE 13G/A filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Aytu BioPharma Inc has 36 institutional holders and institutional ownership of 36.4%.

Insider activity

Insiders reported 15 transactions (3 buys, 1 sells) across 8 reporting insiders, with a net reported value of $132.9K.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2024-09-26 (recurring since 2020-02-14) — source filing. The authoritative details are those stated in the filing itself.

Active non-reliance notice on previously issued financial statements (8-K Item 4.02), most recently filed 2023-02-21 (recurring since 2023-02-21) — source filing. The authoritative details are those stated in the filing itself.

Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2022-11-22 (recurring since 2020-02-21) — source filing. The authoritative details are those stated in the filing itself.

Related companies

Werewolf Therapeutics Inc (HOWL) · ENVOY MEDICAL INC (COCH) · Clene Inc (CLNN) · ORGANIGRAM GLOBAL INC (OGI) · ANNOVIS BIO INC (ANVS) · SAFE PRO GROUP INC (SPAI)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-25.